A German study identified several comorbid diseases that have a high prevalence in patients with chronic urticaria, psoriasis, and atopic dermatitis (AD); thus, adding to their burden of disease .
Data for this study was obtained from a representative subset of anonymised German health insurance claims containing information of about 4 million insured people . Included were 2,561 adults and 216 paediatric patients with chronic spontaneous urticaria (CSU). For psoriasis, 72,738 adults were included and 747 paediatric patients, as well as 61,030 adults with AD and 30,180 children. The study also contained a reference group of 3,243,744 adults and 576,234 children/adolescents matched according to age and sex to investigate for comorbidity prevalence. Of the adults, 50% were male, and 51.4% of the children were male. Mean age of adult and paediatric patients was 52.2 years and 10.6 years for CSU. Respective values for psoriasis were 59.1 and 12.5, for AD 47.7 and 7.72. All patients had to be observable throughout the entire year of 2017. They were included based on their specific ICD-10 code for diagnosis.
Over all 3 diseases, the researchers found correspondingly increased frequencies for anxiety and depression in adult patients when compared with the matched subjects. The paediatric patients were more prone to these diagnoses than the controls, but not as much as the grown-ups. Looking especially at results for CSU, Dr Karsten Weller (Charité University Hospital, Germany) and his fellow researchers found augmented values for prevalence of comorbidity for allergic rhinitis (24.8%), arthropathies (44.5%), dermatitis and eczema (38.4%), and hypertension (41.7%) in adults with CSU. Rates for adults with psoriasis and AD were similar with the exception of autoimmune thyreoiditis, which was clearly more frequent in CSU.
In children with CSU, concurrent diagnoses of asthma (15.6%) and allergic rhinitis (25.6%) stood out. The corresponding rates in the control group were 6.03% and 5.53%, respectively. This large data analysis confirms a high prevalence of physical and psychiatric comorbidities in adult and paediatric CSU patients. The authors emphasised that due to their very specific inclusion criteria for CSU patients in this study, they probably underestimated the prevalence of CSU in Germany.
- Weller K, et al. P0930, EADV 2019, 9-13 Oct, Madrid, Spain.
« IL-17 blocker: effective and safe in patients with comorbidities Next Article
The Rosacea Tracker may aid clinical decision-making »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
Selective TYK2 inhibitor effective in moderate-to-severe plaque psoriasis
IL-17A and IL-17F blockade remarkably effective in psoriasis